370 related articles for article (PubMed ID: 28640385)
21. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.
Raymakers AJN; Costa S; Cameron D; Regier DA
BMC Cancer; 2020 Oct; 20(1):992. PubMed ID: 33050897
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
[TBL] [Abstract][Full Text] [Related]
24. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
[TBL] [Abstract][Full Text] [Related]
26. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].
Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S
Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698
[TBL] [Abstract][Full Text] [Related]
27. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
[TBL] [Abstract][Full Text] [Related]
29. Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary.
Husi K; Szabó R; Pinczés LI; Földeák D; Dudley R; Szomor Á; Koller B; Gopcsa L; Illés Á; Miltényi Z
Ann Hematol; 2023 Sep; 102(9):2555-2563. PubMed ID: 37428200
[TBL] [Abstract][Full Text] [Related]
30. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
32. Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
Szabo SM; Hirji I; Johnston KM; Juarez-Garcia A; Connors JM
PLoS One; 2017; 12(10):e0180261. PubMed ID: 28991893
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
Forlenza CJ; Rosenzweig J; Mauguen A; Buhtoiarov I; Cuglievan B; Dave H; Deyell RJ; Flerlage JE; Franklin AK; Krajewski J; Leger KJ; Marks LJ; Norris RE; Pacheco M; Willen F; Yan AP; Harker-Murray PD; Giulino-Roth L
Blood Adv; 2023 Jul; 7(13):3225-3231. PubMed ID: 36897253
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ
Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
[TBL] [Abstract][Full Text] [Related]
38. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
Tsirigotis P; Vassilakopoulos T; Batsis I; Bousiou Z; Gkirkas K; Sakellari I; Kaloyannidis P; Roussou P; Pangalis GA; Moschogiannis M; Vassilopoulos G; Repousis P; Megalakaki A; Michalis E; Kalpadakis C; Papadaki HA; Kotsianidis I; Hatzimichael E; Spyridonidis A; Anargyrou K; Poulakidas E; Giannoullia P; Apostolidis I; Stamouli M; Konstantopoulos K; Pappa V; Panayiotidis P; Harhalakis N; Anagnostopoulos A; Angelopoulou M
Hematol Oncol; 2018 Oct; 36(4):645-650. PubMed ID: 29882363
[TBL] [Abstract][Full Text] [Related]
39. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
Angelopoulou MK; Vassilakopoulos TP; Batsis I; Sakellari I; Gkirkas K; Pappa V; Giannoulia P; Apostolidis I; Apostolopoulos C; Roussou P; Panayiotidis P; Dimou M; Kyrtsonis MC; Palassopoulou M; Vassilopoulos G; Moschogiannis M; Kalpadakis C; Margaritis D; Spyridonidis A; Michalis E; Anargyrou K; Repousis P; Hatzimichael E; Bousiou Z; Poulakidas E; Grentzelias D; Harhalakis N; Pangalis GA; Anagnostopoulos A; Tsirigotis P
Hematol Oncol; 2018 Feb; 36(1):174-181. PubMed ID: 28219112
[TBL] [Abstract][Full Text] [Related]
40. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
